Close Menu

NEW YORK – Germany-based immuno-oncology company Affimed today announced that it had successfully dosed its first patient with AFM24, an EGFR- and CD16A-binding innate cell engager therapy.

The news marks the start of the company's Phase I/IIb trial of AFM24 in adult patients with EGFR-positive advanced solid tumors. The open-label, non-randomized, multi-center study will assess the maximum tolerated dose of AFM24 as a monotherapy in patients whose disease has progressed after previous lines of treatment, as well as gather preliminary evidence on safety and efficacy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.